Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial

Published:2024-02 Issue:2 Volume:25 Page:184-197
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fan Lei,Wang Zhong-Hua,Ma Lin-Xiaoxi,Wu Song-Yang,Wu Jiong,Yu Ke-Da,Sui Xin-Yi,Xu Ying,Liu Xi-Yu,Chen Li,Zhang Wen-Juan,Jin Xi,Xiao Qin,Shui Ruo-Hong,Xiao Yi,Wang Han,Yang Yun-Song,Huang Xiao-Yan,Cao A-Yong,Li Jun-Jie,Di Gen-Hong,Liu Guang-Yu,Yang Wen-Tao,Hu Xin,Xia Yan,Liang Qian-Nan,Jiang Yi-Zhou,Shao Zhi-Ming

Funder

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

Publisher

Elsevier BV

Reference29 articles.

1. Breast cancer;Loibl;Lancet,2021

2. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer;Robson;Ann Oncol,2019

3. Sacituzumab govitecan in metastatic triple-negative breast cancer;Bardia;N Engl J Med,2021

4. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer;Modi;N Engl J Med,2022

5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial;Cortes;Lancet,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subtypbasierte Therapie des metastasierten triple-negativen Mammakarzinoms;TumorDiagnostik & Therapie;2024-09

2. Subtypbasierte Therapie des metastasierten triple-negativen Mammakarzinoms;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-09

3. Subtypbasierte Therapie des metastasierten triple-negativen Mammakarzinoms;Frauenheilkunde up2date;2024-08

4. Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance;npj Precision Oncology;2024-07-26

5. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies;Frontiers in Oncology;2024-05-28